ImmuneRegen BioSciences' Homspera(TM) Deemed Dermally Non-Toxic
March 03 2004 - 10:00AM
PR Newswire (US)
ImmuneRegen BioSciences' Homspera(TM) Deemed Dermally Non-Toxic
Pre-Clinical Studies Bode Well for Future Hair Loss Applications
SCOTTSDALE, Ariz., March 3 /PRNewswire-FirstCall/ -- ImmuneRegen
BioSciences, a wholly owned subsidiary of IR BioSciences Holdings,
Inc. (BULLETIN BOARD: IRBH) , today announced their toxicity study
for their proprietary compound Homspera showed no levels of
toxicity, such as skin irritation, in tested animals. With these
results, the company is moving forward in targeting male pattern
baldness as a potential application for Homspera. The study was
performed by AppTec Laboratory Services of St. Paul, MN and was
designed to evaluate the allergenic potential or sensitizing
capacity for the company's substance P compound. According to the
AppTec results report, "ImmuneRegen BioSciences, Inc., Homspera
[Sar9, met (O2)11] -- Substance P ... was classified as acceptable
in regard to dermal sensitization." "Obviously we're thrilled with
these test results," states Michael K. Wilhelm, president of IR
BioSciences Holdings, Inc. "We're currently researching the
effectiveness of Homspera in topical applications for conditions
such as male pattern baldness and loss of hair from chemotherapy.
These results put us one stepcloser to making these applications a
reality." About the study The study utilized fifteen guinea pigs,
ten experimental and five controls. Patches with topical doses of
Homspera [Sar9, met (O2)11] -- Substance P were applied to the
shaved left flanks of the ten experimental guinea pigs, which were
then bandaged to secure the patches. The bandaging and patches were
removed after six to eight hours of exposure and each guinea pig
was checked after roughly 24 hours for signs of erythema and edema.
The procedure was repeated once a week for three weeks for a total
of three inductions. The tested guinea pigs showed no signs of
erythema or edema. Fourteen days after completing the topical
induction process, patches with topical doses were appliedto the
shaved right flanks of the ten experimental guinea pigs, which were
then bandaged to secure the patches. Again, the bandaging and
patches were removed after six to eight hours of exposure. At the
24, 48 and 72-hour marks, each testing area waswiped gently with a
70% isporpyl alcohol-soaked gauze sponge and was observed for
irritation and sensitization reactions. Again, the tested guinea
pigs showed no signs of erythema or edema. About AppTec AppTec
Laboratory Services is a unique single source for the
biopharmaceutical/biotechnology and medical device/medical product
industries -- offering testing, contract research and development,
and specialized cGMP manufacturing services. About IR BioSciences
Holdings, Inc. IR BioSciences Holdings, Inc. (OTC:IRBH) (BULLETIN
BOARD: IRBH) , formed in 2003, is the sole owner of ImmuneRegen
BioSciences, Inc., a biotechnology company engaged in the research
and development of applications utilizing modified Substance P, a
naturally occurring immunomodulator. Derived from homeostatic
substance P, ImmuneRegen has named their proprietary compound
"Homspera." The Company's initial focus is on the continuing
development of Homspera for various applications for use in
improving pulmonary function and stimulating the human immune
system. For more information, please visit the company's website at
http://www.immuneregen.com/ . About Homspera ImmuneRegen's patents
and continued substance P research are derived from discoveries
made during research funded by the Air Force Office of Scientific
Research in the early 1990s. During this research, Dr. Mark Witten
and his associates observed that the exposure of animals to jet
fuels resulted in pathological changes in the lung and immune
systems of those exposed. It was also observed that such exposure
resulted in depletion of substance P from the lungs of the animals.
These studies further showed that the administration of substance P
may help prevent and reverse the effects of jet fuel exposure in
the lungs, as well as protect and regenerate the immune system. The
immune findings led to early research on the treatment of exposure
to acute radiation and on the possible reversal of lung damage
caused by ARDS and cigarette smoke. Statements about the Company's
future expectations, including future revenues and earnings, and
all other statements in this press release other than historical
facts, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Securities Litigation Reform Act of 1995. The Company
intends that such forward-looking statements be subject to the safe
harbors created thereby. The Company's actual results could differ
materially from expected results as a result of a number of
factors, including the uncertainties inherent in research
collaborations, clinical trials and product development programs,
the evaluation of potential opportunities, the level of corporate
expenditures, capital market conditions, and others set forth in
the Company's periodic report on Form 8-K as filed with the
Securities and Exchange Commission on July 7, 2003. DATASOURCE:
ImmuneRegen BioSciences, Inc. CONTACT: Media, Michelle Derden of
Spelling Communications, +1-310-477-9500, ; or Investors, Tony
Schor of InvestorAwareness, +1-847-945-2222, , both for ImmuneRegen
BioSciences, Inc. Web site: http://www.immuneregen.com/
Copyright